These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 24108150)

  • 1. AAV-encoded OTC activity persisting to adulthood following delivery to newborn spf(ash) mice is insufficient to prevent shRNA-induced hyperammonaemia.
    Cunningham SC; Kok CY; Spinoulas A; Carpenter KH; Alexander IE
    Gene Ther; 2013 Dec; 20(12):1184-7. PubMed ID: 24108150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction and prevention of severe hyperammonemia in the spfash mouse model of ornithine transcarbamylase deficiency using shRNA and rAAV-mediated gene delivery.
    Cunningham SC; Kok CY; Dane AP; Carpenter K; Kizana E; Kuchel PW; Alexander IE
    Mol Ther; 2011 May; 19(5):854-9. PubMed ID: 21386824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term correction of ammonia metabolism and prolonged survival in ornithine transcarbamylase-deficient mice following liver-directed treatment with adeno-associated viral vectors.
    Moscioni D; Morizono H; McCarter RJ; Stern A; Cabrera-Luque J; Hoang A; Sanmiguel J; Wu D; Bell P; Gao GP; Raper SE; Wilson JM; Batshaw ML
    Mol Ther; 2006 Jul; 14(1):25-33. PubMed ID: 16677864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AAV2/8-mediated correction of OTC deficiency is robust in adult but not neonatal Spf(ash) mice.
    Cunningham SC; Spinoulas A; Carpenter KH; Wilcken B; Kuchel PW; Alexander IE
    Mol Ther; 2009 Aug; 17(8):1340-6. PubMed ID: 19384294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Exon-Specific Small Nuclear U1 RNA (ExSpeU1) Improves Hepatic OTC Expression in a Splicing-Defective
    Balestra D; Ferrarese M; Lombardi S; Ziliotto N; Branchini A; Petersen N; Bosma P; Pinotti M; van de Graaf SFJ
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33228018
    [No Abstract]   [Full Text] [Related]  

  • 6. Stable transduction of the neonatal mouse liver using a hybrid rAAV/sleeping beauty transposon gene delivery system.
    Cunningham SC; Zakas PM; Sasaki N; van Dijk EB; Zhu E; Fu Y; Salomon WE; Citorik RJ; Rubens JR; Cotta-Ramusino C; Querbes W; Alexander IE
    J Gene Med; 2024 Aug; 26(8):e3726. PubMed ID: 39160647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling correction of severe urea cycle defects in the growing murine liver using a hybrid recombinant adeno-associated virus/piggyBac transposase gene delivery system.
    Cunningham SC; Siew SM; Hallwirth CV; Bolitho C; Sasaki N; Garg G; Michael IP; Hetherington NA; Carpenter K; de Alencastro G; Nagy A; Alexander IE
    Hepatology; 2015 Aug; 62(2):417-28. PubMed ID: 26011400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A mutation-independent CRISPR-Cas9-mediated gene targeting approach to treat a murine model of ornithine transcarbamylase deficiency.
    Wang L; Yang Y; Breton C; Bell P; Li M; Zhang J; Che Y; Saveliev A; He Z; White J; Latshaw C; Xu C; McMenamin D; Yu H; Morizono H; Batshaw ML; Wilson JM
    Sci Adv; 2020 Feb; 6(7):eaax5701. PubMed ID: 32095520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of tumors arising in male B6C3F1 mice with and without AAV vector delivery to liver.
    Bell P; Moscioni AD; McCarter RJ; Wu D; Gao G; Hoang A; Sanmiguel JC; Sun X; Wivel NA; Raper SE; Furth EE; Batshaw ML; Wilson JM
    Mol Ther; 2006 Jul; 14(1):34-44. PubMed ID: 16682254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correction of ornithine transcarbamylase deficiency in adult spf(ash) mice and in OTC-deficient human hepatocytes with recombinant adenoviruses bearing the CAG promoter.
    Kiwaki K; Kanegae Y; Saito I; Komaki S; Nakamura K; Miyazaki JI; Endo F; Matsuda I
    Hum Gene Ther; 1996 May; 7(7):821-30. PubMed ID: 8860834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical evaluation of a clinical candidate AAV8 vector for ornithine transcarbamylase (OTC) deficiency reveals functional enzyme from each persisting vector genome.
    Wang L; Morizono H; Lin J; Bell P; Jones D; McMenamin D; Yu H; Batshaw ML; Wilson JM
    Mol Genet Metab; 2012 Feb; 105(2):203-11. PubMed ID: 22133298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice.
    Yang Y; Wang L; Bell P; McMenamin D; He Z; White J; Yu H; Xu C; Morizono H; Musunuru K; Batshaw ML; Wilson JM
    Nat Biotechnol; 2016 Mar; 34(3):334-8. PubMed ID: 26829317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained correction of OTC deficiency in spf( ash) mice using optimized self-complementary AAV2/8 vectors.
    Wang L; Wang H; Morizono H; Bell P; Jones D; Lin J; McMenamin D; Yu H; Batshaw ML; Wilson JM
    Gene Ther; 2012 Apr; 19(4):404-10. PubMed ID: 21850052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo assessment of mutations in OTC for dominant-negative effects following rAAV2/8-mediated gene delivery to the mouse liver.
    Ginn SL; Cunningham SC; Zheng M; Spinoulas A; Carpenter KH; Alexander IE
    Gene Ther; 2009 Jun; 16(6):820-3. PubMed ID: 19357713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AAV gene therapy corrects OTC deficiency and prevents liver fibrosis in aged OTC-knock out heterozygous mice.
    Wang L; Bell P; Morizono H; He Z; Pumbo E; Yu H; White J; Batshaw ML; Wilson JM
    Mol Genet Metab; 2017 Apr; 120(4):299-305. PubMed ID: 28283349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive characterization of ureagenesis in the spf
    Allegri G; Deplazes S; Rimann N; Causton B; Scherer T; Leff JW; Diez-Fernandez C; Klimovskaia A; Fingerhut R; Krijt J; Kožich V; Nuoffer JM; Grisch-Chan HM; Thöny B; Häberle J
    J Inherit Metab Dis; 2019 Nov; 42(6):1064-1076. PubMed ID: 30714172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retroviral-mediated gene transfer of human ornithine transcarbamylase into primary hepatocytes of spf and spf-ash mice.
    Grompe M; Jones SN; Loulseged H; Caskey CT
    Hum Gene Ther; 1992 Feb; 3(1):35-44. PubMed ID: 1562638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficient mitochondrial import of newly synthesized ornithine transcarbamylase (OTC) and correction of secondary metabolic alterations in spf(ash) mice following gene therapy of OTC deficiency.
    Zimmer KP; Bendiks M; Mori M; Kominami E; Robinson MB; Ye X; Wilson JM
    Mol Med; 1999 Apr; 5(4):244-53. PubMed ID: 10448647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sleeping Beauty mRNA-LNP enables stable rAAV transgene expression in mouse and NHP hepatocytes and improves vector potency.
    Zakas PM; Cunningham SC; Doherty A; van Dijk EB; Ibraheim R; Yu S; Mekonnen BD; Lang B; English EJ; Sun G; Duncan MC; Benczkowski MS; Altshuler RC; Singh MJ; Kibbler ES; Tonga GY; Wang ZJ; Wang ZJ; Li G; An D; Rottman JB; Bhavsar Y; Purcell C; Jain R; Alberry R; Roquet N; Fu Y; Citorik RJ; Rubens JR; Holmes MC; Cotta-Ramusino C; Querbes W; Alexander IE; Salomon WE
    Mol Ther; 2024 Oct; 32(10):3356-3371. PubMed ID: 38981468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the transfer and expression in mice of an enzyme-encoding gene using a human adenovirus vector.
    Stratford-Perricaudet LD; Levrero M; Chasse JF; Perricaudet M; Briand P
    Hum Gene Ther; 1990; 1(3):241-56. PubMed ID: 2081192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.